The data posted online, which are expected to be discussed in a company earnings call on Wednesday morning, suggest that antibody levels against the Delta variant in people ages 18 to 55 who receive a third dose of vaccine are greater than five-fold than following a second dose.

Among people ages 65 to 85, the Pfizer data suggest that antibody levels against the Delta variant after receiving a third dose of vaccine are greater than 11-fold than following a second dose.

There’s “estimated potential for up to 100-fold increase in Delta neutralization post-dose three compared to pre-dose three,” researchers wrote in the Pfizer data slides.